JFG
RLMD icon

Jefferies Financial Group’s Relmada Therapeutics RLMD Stock Holding History

Jefferies Financial Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$112K Sell
16,120
-5,535
-26% -$26.2K ﹤0.01% 1586
2025
Q4 		$105K Buy
+21,655
New +$72.6K ﹤0.01% 1697

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Jefferies Financial Group's RLMD Position: Q1 2026 in Review

Jefferies Financial Group reduced its Relmada Therapeutics (RLMD) stake by 26% in Q1 2026, selling an estimated $26.2K and leaving 16,120 shares worth $112K. The position accounts for ﹤0.01% of the portfolio, ranked #1586.

Jefferies Financial Group first reported a position in RLMD in Q4 2025 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Jefferies Financial Group held 16,120 shares of Relmada Therapeutics worth $112K as of Q1 2026.
  • Jefferies Financial Group sold 5,535 Relmada Therapeutics shares in Q1 2026, an estimated $26.2K.
  • Relmada Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q1 2026, its #1586 holding.
  • Jefferies Financial Group first reported a position in Relmada Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.